Contact Us
Drug Search Results
More Filters [+]

Doxazosin

Alternative Names: doxazosin, cardura
Latest Update: 2024-11-20
Latest Update Note: Clinical Trial Update

Product Description

Doxazosin belongs to the general class of medicines called antihypertensives. It is used to treat high blood pressure (hypertension). Doxazosin works by relaxing blood vessels so that blood passes through them more easily. This helps to lower blood pressure. Doxazosin is also used to treat benign (noncancerous) enlargement of the prostate (benign prostatic hyperplasia [BPH]). (Sourced from: https://www.mayoclinic.org/drugs-supplements/doxazosin-oral-route/side-effects/drg-20063546?p=1)

Mechanisms of Action: ADRA1A Antagonist,ADRA1B Antagonist,ADRA1D Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Algeria | Argentina | Australia | Austria | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Jordan | Korea | Latvia | Lebanon | Lithuania | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Venezuela | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Doxazosin

Countries in Clinic: Germany

Active Clinical Trial Count: 2

Highest Development Phases

Phase 2: Stress Disorders, Post-Traumatic

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
ClonDoTrial

P2

Active, not recruiting

Stress Disorders, Post-Traumatic

2024-12-20

ClonDoTrial

P2

Recruiting

Stress Disorders, Post-Traumatic

2024-07-31

Recent News Events

Date

Type

Title

03/22/2024

News Article

 U.S. FDA Approves OPSYNVI® (macitentan and tadalafil) as the First and Only Once-Daily Single-Tablet Combination Therapy for Patients with Pulmonary Arterial Hypertension (PAH)

10/30/2023

News Article

 Petros Pharmaceuticals Petros Pharmaceuticals Developing Artificial Intelligence Technology for Phase 2 Equivalent Study for STENDRA(R)

10/19/2023

News Article

 Following Encouraging FDA Feedback Petros Pharmaceuticals Initiates Self-Selection (Phase 2-Equivalent) Study for STENDRA

10/04/2023

News Article

 Petros Pharmaceuticals Announces Positive Outcomes in Label Comprehension Study for Potential OTC STENDRA Label

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions